Needham & Company

Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Friday, July 28, 2023

In addition, Inozyme has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • In addition, Inozyme has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
  • All of the shares of common stock are being offered by Inozyme.
  • BofA Securities, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering.
  • 333-258702) relating to the shares of common stock offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2021 and became effective on August 23, 2021.

Disruption Takes the Main Stage at Fiber Broadband Association’s Fiber Connect 2023

Retrieved on: 
Tuesday, July 18, 2023

The Fiber Broadband Association today announced general session keynotes and Operator Light Talks planned for Fiber Connect 2023 , August 20-23, 2023, in Orlando, Fla.

Key Points: 
  • The Fiber Broadband Association today announced general session keynotes and Operator Light Talks planned for Fiber Connect 2023 , August 20-23, 2023, in Orlando, Fla.
  • Fiber Connect is the world’s largest fiber broadband event, and this year’s program will feature new themes and content styles.
  • “Fiber Connect grows every year because we present the topics that matter most to network operators, broadband providers, municipalities, electric cooperatives, and others that are building fiber broadband networks to connect North America,” said Evann Freeman, EPB Director of Government Relations and Fiber Broadband Association Conference Committee Chair.
  • “While the fiber broadband industry is experiencing its largest investment cycle ever, the Fiber Broadband Association is delivering content and networking opportunities to help guide the industry with best practices and explore what is possible once fiber networks reach everyone, everywhere.”
    Operator Light Talks are a new addition to the Fiber Connect agenda this year.

Coherent Appoints Paul Silverstein as VP, Investor Relations & Corporate Communications

Retrieved on: 
Tuesday, July 11, 2023

PITTSBURGH, July 11, 2023 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and laser technology, today announced that Paul Silverstein has been appointed as Vice President, Investor Relations & Corporate Communications, reporting to Chair and CEO Dr. Vincent D. Mattera, Jr.

Key Points: 
  • PITTSBURGH, July 11, 2023 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and laser technology, today announced that Paul Silverstein has been appointed as Vice President, Investor Relations & Corporate Communications, reporting to Chair and CEO Dr. Vincent D. Mattera, Jr.
    “The appointment of Paul Silverstein to head up our investor relations and corporate communications teams is the next step in expanding our brand recognition with a renewed focus on investors,” said Dr. Mattera.
  • “Paul will play a pivotal role in representing our company to the investment community.
  • Most recently, he spent the past 10 years as a managing director and senior analyst at Cowen Inc.
  • Prior to his career in equity research, he practiced corporate and securities law as an associate at Pryor Cashman Sherman & Flynn and at Weil, Gotshal & Manges.

Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Retrieved on: 
Friday, June 9, 2023

After giving effect to the sale of these additional shares, the total gross proceeds to Phathom from the offering were approximately $150.3 million, before deducting the underwriting discounts and commissions and other offering expenses.

Key Points: 
  • After giving effect to the sale of these additional shares, the total gross proceeds to Phathom from the offering were approximately $150.3 million, before deducting the underwriting discounts and commissions and other offering expenses.
  • Phathom intends to use the net proceeds from the offering to fund the clinical development of vonoprazan, pre-commercial activities and commercialization expenses and for working capital and general corporate purposes.
  • Jefferies and Evercore ISI acted as joint bookrunning managers for the offering.
  • A final prospectus supplement relating to the offering has been filed with the SEC.

Mobileye Announces Pricing of Secondary Offering of Shares of Class A Common Stock

Retrieved on: 
Thursday, June 8, 2023

Mobileye Global Inc. (Nasdaq: MBLY) (“Mobileye”) today announced the pricing of a previously announced underwritten secondary public offering of 38,500,000 shares of Mobileye’s Class A common stock by Intel Overseas Funding Corporation, a wholly owned subsidiary of Intel Corporation (the “Selling Stockholder”), at a price of $42.00 per share.

Key Points: 
  • Mobileye Global Inc. (Nasdaq: MBLY) (“Mobileye”) today announced the pricing of a previously announced underwritten secondary public offering of 38,500,000 shares of Mobileye’s Class A common stock by Intel Overseas Funding Corporation, a wholly owned subsidiary of Intel Corporation (the “Selling Stockholder”), at a price of $42.00 per share.
  • The Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 5,775,000 shares of Mobileye’s Class A common stock.
  • The offering is expected to close on June 12, 2023, subject to customary closing conditions.
  • Mobileye is not selling any shares of Class A common stock in the offering and will not receive any proceeds from the sale of the shares being offered by the Selling Stockholder.

TNL Mediagene, a leading Asian digital-media company, agrees to become publicly listed company on Nasdaq through merger with Blue Ocean Acquisition Corp

Retrieved on: 
Tuesday, June 6, 2023

"By combining forces, TNL and Mediagene have created a first-class, pan-Asian digital-media group," Mediagene CEO and founder Motoko Imada said.

Key Points: 
  • "By combining forces, TNL and Mediagene have created a first-class, pan-Asian digital-media group," Mediagene CEO and founder Motoko Imada said.
  • Pursuant to the business combination agreement for the transaction, Blue Ocean will merge with a wholly owned subsidiary of TNL Mediagene with Blue Ocean surviving the merger as a wholly owned subsidiary of TNL Mediagene (the "Merger"), and TNL Mediagene becoming a publicly listed company on the NASDAQ.
  • As a result of the Merger, outstanding shares and warrants of Blue Ocean will be canceled and converted into the right to receive equivalent shares and warrants of TNL Mediagene.
  • The Boards of Directors of TNL Mediagene and Blue Ocean, respectively, have approved the transaction.

Navitas Semiconductor Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, June 5, 2023

After giving effect to the full exercise of the option to purchase additional shares, the total number of shares sold by Navitas in the offering increased to 11,500,000 shares.

Key Points: 
  • After giving effect to the full exercise of the option to purchase additional shares, the total number of shares sold by Navitas in the offering increased to 11,500,000 shares.
  • Aggregate gross proceeds, before deducting underwriting discounts and commissions and offering expenses, were $92.0 million.
  • The issuance and sale of the additional shares closed on June 5, 2023.
  • Navitas intends to use the net proceeds from the offering for working capital and other general corporate purposes, including potential acquisitions or strategic manufacturing investments.

Navitas Semiconductor Announces Pricing of Public Offering of Class A Common Stock

Retrieved on: 
Wednesday, May 24, 2023

TORRANCE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Navitas Semiconductor Corporation (Nasdaq: NVTS), an industry leader in next-generation power semiconductors, announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its Class A common stock at a price to the public of $8.00 per share.

Key Points: 
  • TORRANCE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Navitas Semiconductor Corporation (Nasdaq: NVTS), an industry leader in next-generation power semiconductors, announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its Class A common stock at a price to the public of $8.00 per share.
  • All of the shares in the offering are being offered by Navitas.
  • The gross proceeds to Navitas from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $80.0 million.
  • In addition, Navitas has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock at the public offering price, less underwriting discounts and commissions.

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, May 24, 2023

FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 11,125,000 shares of its common stock at a price to the public of $11.75 per share.

Key Points: 
  • FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 11,125,000 shares of its common stock at a price to the public of $11.75 per share.
  • The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130.7 million.
  • In addition, Phathom has granted the underwriters a 30-day option to purchase up to an additional 1,668,750 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about May 26, 2023, subject to satisfaction of customary closing conditions.

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, May 23, 2023

FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Key Points: 
  • FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
  • In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the shares of its common stock offered in the public offering.
  • There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Phathom intends to use the net proceeds from the proposed offering to fund the clinical development of vonoprazan, pre-commercial activities and commercialization expenses and for working capital and general corporate purposes.